Related Experiment Video

Updated: Jun 10, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Resistance to activated protein C and ischemic arterial disease in a young man

Igor Alexandre Côrtes de Menezes1, Rafael Fernandes Romani, Yuki Schneider Aoki

  • 1Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazil.

Arquivos Brasileiros De Cardiologia
|August 24, 2010
PubMed

Insights

Activated protein C resistance (APCR), linked to factor V Leiden, is a known risk for venous clots. This case explores its potential role in arterial blockages, offering new insights into thrombotic disease.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Genetics

Background:

  • Activated protein C resistance (APCR) is a significant risk factor for venous thromboembolism (VTE).
  • The role of APCR, particularly factor V Leiden, in arterial thrombosis remains controversial.
  • Understanding thrombotic risk factors is crucial for managing cardiovascular and cerebrovascular diseases.

Observation:

  • A young patient presented with a history of coronary artery disease, multiple cerebrovascular lesions, and peripheral artery disease.
  • Diagnostic investigations were conducted to determine the underlying etiology of the patient's complex vascular conditions.
  • The patient exhibited symptoms suggestive of widespread arterial obstruction.

Findings:

  • The diagnostic workup identified Activated Protein C Resistance (APCR) as a potential primary cause.
  • Factor V Leiden mutation was assessed as the underlying genetic factor for APCR.
  • APCR was implicated as the possible etiology for the patient's combined arterial and venous thrombotic events.

Implications:

  • This case highlights the potential of APCR as a unifying etiology for both venous and arterial thromboembolism.
  • Further research into the role of factor V Leiden in arterial disease is warranted.
  • Identifying APCR may lead to targeted anticoagulant therapies for patients with unexplained thrombotic events.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...